Earnings In Brief
This article was originally published in The Gray Sheet
Executive Summary
CryoCath's AF results: Arctic Front cryoablation system with FlexCath deflectable sheath to treat atrial fibrillation achieved a chronic efficacy rate of over 80% at 6 months in a 20-patient U.S. trial, according to CryoCath CEO Steve Arless. The firm reported no long-term safety issues, though two patients did have to be re-treated early on. "If the data continue to build as with the first 20 patients, we'll certainly corner the vast majority of the [atrial fibrillation] market. But the interesting thing we will address longer term is what role [Arctic Front] will play in the treatment of ventricular tachycardia, where implantable defibrillators play a huge role right now," Arless said. For the quarter ended Dec. 31, the firm reported revenue of $8.9 mil., up 48% over the prior-year period...